The appropriate, individual treatment of men with metastatic and non-metastatic forms of castration-resistant prostate cancer (CRPC) has become vastly more complicated over the past 5 years. After the approval of docetaxel (Taxotere)-based chemotherapy in 2004, which was the first time any drug had been shown to be extend survival in the treatment of CRPC, we […]![]()
